Loading…
The Pennant Group, Inc. provides healthcare services in the United States. It operates in two segments, Home Health and Hospice Services, and Senior Living Services. The company offers home health services, including clinical services, such as nursing, speech, occupational and physical therapy, medical social work, and home health aide services; and hospice services comprising clinical care, education, and counseling services for the physical, spiritual, and psychosocial needs of terminally ill patients and their families. It also provides senior living services, such as residential accommodations, activities, meals, housekeeping, and assistance in the activities of daily living to seniors who are independent or who require some support. The company operates home health, hospice, and home care agencies, as well as senior living communities in Alabama, Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Tennessee, Texas, Utah, Washington, Wisconsin, and Wyoming. The Company was incorporated in 2019 and is headquartered in Eagle, Idaho.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $948M | $61M | $30M | $36M | 7.9% | 36.3% | 31.1% |
| 2024 | $695M | $44M | $23M | $30M | 7.2% | 27.6% | 68.6% |
| 2023 | $545M | $31M | $13M | $25M | 9.2% | 15.1% | 101.4% |
| 2022 | $473M | $18M | $7M | $-5M | 5.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 473.24 | 544.89 | 695.24 | 947.71 |
| Cost Of Revenue | 414.66 | 477.86 | 601.48 | 817.20 |
| Gross Profit | 58.59 | 67.04 | 93.76 | 130.50 |
| Operating Expense | 38.88 | 41.80 | 56.33 | 79.61 |
| Operating Income | 19.70 | 25.24 | 37.43 | 50.89 |
| EBITDA | 17.61 | 30.64 | 44.44 | 60.85 |
| EBIT | 12.71 | 25.51 | 38.32 | 52.31 |
| Pretax Income | 8.89 | 19.58 | 31.37 | 45.63 |
| Tax Provision | 1.65 | 5.67 | 7.03 | 11.87 |
| Net Income | 6.64 | 13.38 | 22.56 | 29.58 |
| Net Income Common Stockholders | 6.64 | 13.38 | 22.56 | 29.58 |
| Total Expenses | 453.54 | 519.65 | 657.81 | 896.82 |
| Interest Expense | 3.82 | 5.92 | 6.96 | 6.68 |
| Selling General And Administration | 33.98 | 36.67 | 50.21 | 71.08 |
| Normalized EBITDA | 24.57 | 30.71 | 43.76 | 59.85 |
| Normalized Income | 12.32 | 13.43 | 22.03 | 28.84 |
| Basic EPS | 0.23 | 0.45 | 0.72 | 0.86 |
| Diluted EPS | 0.22 | 0.44 | 0.70 | 0.84 |
| Tax Effect Of Unusual Items | -1.29 | -0.02 | 0.15 | 0.26 |
| Tax Rate For Calcs | 0.18 | 0.29 | 0.22 | 0.26 |
| Total Unusual Items | -6.96 | -0.07 | 0.68 | 1 |
| Total Unusual Items Excluding Goodwill | -6.96 | -0.07 | 0.68 | 1 |
| Net Income From Continuing Operation Net Minority Interest | 6.64 | 13.38 | 22.56 | 29.58 |
| Reconciled Depreciation | 4.90 | 5.13 | 6.12 | 8.54 |
| Reconciled Cost Of Revenue | 414.66 | 477.86 | 601.48 | 817.20 |
| Net Interest Income | -3.82 | -5.92 | -6.96 | -6.68 |
| Net Income From Continuing And Discontinued Operation | 6.64 | 13.38 | 22.56 | 29.58 |
| Rent Expense Supplemental | 38.02 | 39.76 | 43.03 | 48.70 |
| Total Operating Income As Reported | 12.74 | 25.17 | 38.12 | 51.89 |
| Diluted Average Shares | 30.16 | 30.19 | 32 | 35.32 |
| Basic Average Shares | 29.06 | 29.86 | 31.19 | 34.56 |
| Diluted NI Availto Com Stockholders | 6.64 | 13.38 | 22.56 | 29.58 |
| Minority Interests | -0.60 | -0.53 | -1.78 | -4.19 |
| Net Income Including Noncontrolling Interests | 7.24 | 13.91 | 24.34 | 33.76 |
| Net Income Continuous Operations | 7.24 | 13.91 | 24.34 | 33.76 |
| Other Income Expense | -7 | 0.27 | 0.89 | 1.42 |
| Other Non Operating Income Expenses | -0.03 | 0.34 | 0.21 | 0.42 |
| Special Income Charges | -6.96 | -0.07 | 0.68 | 1 |
| Gain On Sale Of Ppe | -6.96 | -0.07 | 0.68 | 1 |
| Net Non Operating Interest Income Expense | -3.82 | -5.92 | -6.96 | -6.68 |
| Interest Expense Non Operating | 3.82 | 5.92 | 6.96 | 6.68 |
| Depreciation Amortization Depletion Income Statement | 4.90 | 5.13 | 6.12 | 8.54 |
| Depreciation And Amortization In Income Statement | 4.90 | 5.13 | 6.12 | 8.54 |
| General And Administrative Expense | 33.98 | 36.67 | 50.21 | 71.08 |
| Other Gand A | 33.98 | 36.67 | 50.21 | 71.08 |
| Operating Revenue | 473.24 | 544.89 | 695.24 | 947.71 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| The Pennant Group, Inc.this co. | PNTG | $1.1B | 36.56↓ discount | 3.22 | 7.9% | 25.85 |
| EyePoint, Inc. | EYPT | $1.1B | - | 32.47 | -75.8% | -4.95 |
| Pacira BioSciences, Inc. | PCRX | $1.1B | 149.91 | 1.52 | 1.0% | 10.73 |
| CareDx, Inc. | CDNA | $1.1B | - | 3.49 | -7.0% | -124.58 |
| Teladoc Health, Inc. | TDOC | $1.1B |
| - |
| 0.77 |
| -14.5% |
| 39.94 |
| IRADIMED CORPORATION | IRMD | $1.1B | 47.83 | 11.31 | 23.8% | 37.30 |
| Septerna, Inc. | SEPN | $1.1B | - | 2.75 | -12.8% | -8.66 |
| Omeros Corporation | OMER | $1.0B | - | -8.61 | 2.8% | -9.24 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.0B | - | 73.41 | 4.0% | 31.98 |
| Peer Median | - | 98.87 | 3.12 | -3.0% | 2.89 | |